Modern Retina

Check out the latest issue of Modern Retina! Read about how AI is reshaping ophthalmology, mitigating severe vision loss, multimodal imaging for AMD and GA, as well as mentorship, momentum, and a retina podcast. Read now: hubs.li/Q0450NXy0 #Retina #VisionLoss #AMD #GA

Disease mechanisms and treatment goals differ across AMD, DME, and RVO. Our expert panel reviews clinical nuances and how they guide the choice of next-generation anti-VEGF therapy. Watch the discussion: hubs.li/Q03_z0wF0 #Retina #Ophthalmology

Our latest issue is live! Read about the science powering next-generation retinal treatments, custom programs for managing Macular Telangiectasia, and treatment options for reducing fluid fluctuation in retinal disorders. Read now: hubs.li/Q03ZZ87N0 #Retina #MacTel

How are next-generation anti-VEGF agents changing care in AMD, DME, and RVO? Sharon Fekrat, MD, FACS, FASRS, and an expert panel discuss the real-world performance, durability, and safety of aflibercept 8 mg and faricimab. Watch now: hubs.li/Q03Y_T990 #Retina #AntiVEGF

Wishing you a season filled with clear moments and bright perspectives. 🎄👁️ Thank you to the retina specialists whose precision and dedication protect sight at its most critical level, today and all year long. #EyeCareProfessionals #RetinaCare #HappyHolidays

Grateful for the eye-care professionals who bring clarity, comfort, and better vision to patients every day. Wishing you a spec-tacular 👓 and restorative Thanksgiving! 🦃 #thanksgiving #eyecare

Coave Therapeutics has announced its lead gene therapy program, CoTx-10, for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). hubs.li/Q03Vn_yh0

Stephen Tsang, MD, PhD, reviews promising optogenetic therapy results for retinitis pigmentosa and Stargardt disease, enhancing vision and mobility for patients. hubs.li/Q03Vp8Yp0

Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME: hubs.li/Q03Vn_TX0

Q&A: Kenneth Fan on MCO-010 trials for Stargardt disease: hubs.li/Q03VhpLR0

Foundation Fighting Blindness releases 4-year RUSH2A data to public: hubs.li/Q03VshzK0

Post-hoc AREDS2 analysis highlights distinct mechanisms driving GA progression: hubs.li/Q03Vhdhj0

Ocular Therapeutix reaches target enrollment of 555 patients in SOL-R trial: hubs.li/Q03TM2_00

Kenneth C. Fan, MD, MBA, of Retina Consultants of Texas, highlighted findings from the STARLIGHT study at the American Academy of Ophthalmology 2025 annual meeting. hubs.li/Q03TM0v20

FDA accepts resubmitted ONS-5010 BLA from Outlook Therapeutics: hubs.li/Q03TM3qY0

Q&A: Anat Loewenstein discusses the use of home OCT: hubs.li/Q03TD0DH0

New five-year data reveals SYFOVRE significantly delays geographic atrophy progression, enhancing understanding of age-related macular degeneration treatment. hubs.li/Q03TD2Z80

Post-hoc AREDS2 analysis highlights distinct mechanisms driving GA progression: hubs.li/Q03TD3zp0

Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5: hubs.li/Q03TD3VR0

Diana Do, MD, professor of ophthalmology and vice chair of Clinical Affairs at Stanford University's Byers Eye Institute, presented research on aflibercept 8 mg at the 2025 American Academy of Ophthalmology (AAO) meeting. hubs.li/Q03TD33w0